Current and future applications of the anti-IgE antibody omalizumab

References

• AdelrothERakSHaahtelaT2000Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitisJ Allergy Clin Immunol106253910932067
   PubMed Web of Science ®Google Scholar
• AmiriPHaak-FrendschoMRobbinsK1994Anti-immunoglobulin E treatment decreases worm burden and egg production in Schistosoma mansoni-infected normal and interferon γ knockout miceJ Exp Med18043518006599
   PubMed Web of Science ®Google Scholar
• AyresJGHigginsBChilversER2004Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthmaAllergy59701815180756
   PubMed Web of Science ®Google Scholar
• BeckLASainiS2006Wanted: a study with omalizumab to determine the role of IgE-mediated pathways in atopic dermatitisJ Am Acad Dermato555401
   PubMed Web of Science ®Google Scholar
• BergerPScotto-GomezEMolimardM2007Omalizumab decreases nonspecific airway hyperresponsiveness in vitroAllergy621546117298424
   PubMed Web of Science ®Google Scholar
• BockSAMunoz-FurlongASampsonHA2001Fatalities due to anaphylactic reactions to foodsJ Allergy Clin Immunol107191311150011
   PubMed Web of Science ®Google Scholar
• BouletLPChapmanKRCotéJ1997Inhibitory effect of an anti-IgE antibody E25 on allergen-induced early asthmatic responseAm J Respir Crit Care Med1551835409196083
   PubMed Web of Science ®Google Scholar
• BousquetJLockeyRFMallingHJ1998WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseasesAllergy53Suppl 54
   Google Scholar
• BousquetJWenzelSHolgateS2004Predicting response to omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthmaChest12513788615078749
   PubMed Web of Science ®Google Scholar
• BousquetJCabreraPBerkmanN2005The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthmaAllergy60302815679714
   PubMed Web of Science ®Google Scholar
• BoyceJA2006Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgEJ Allergy Clin Immunol1171415816751006
   PubMed Web of Science ®Google Scholar
• BrownRTurkFDalePBousquetJ2007Cost-effectiveness of omalizumab in patients with severe persistent allergic asthmaAllergy621495317298423
   PubMed Web of Science ®Google Scholar
• BuhlRHantGSolèrM2002The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthmaEur Resp J20108894
   PubMed Web of Science ®Google Scholar
• BurrowsBMartinezFDHalonenM1989Association of asthma with serum IgE levels and skin-test reactivity to allergensN Engl J Med32027172911321
   PubMed Web of Science ®Google Scholar
• BusseWWCorrenJLanierBQ2001Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJ Allergy Clin Immunol1081849011496232
   PubMed Web of Science ®Google Scholar
• CanonicaGWPassalacquaG2003Noninjection routes for immunotherapyJ Allergy Clin Immunol1114374812642818
   PubMed Web of Science ®Google Scholar
• CasaleTBBernsteinILBusseWW1997Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitisJ Allergy Clin Immunol100110219257795
   PubMed Web of Science ®Google Scholar
• CasaleTBCondemiJLaForceC2001Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trialJAMA28629566711743836
   PubMed Web of Science ®Google Scholar
• CasaleTBBusseWWKlineJL2006Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitisJ Allergy Clin Immunol1171344016387596
   PubMed Web of Science ®Google Scholar
• ChervinskyPCasaleTTownleyR2003Omalizumab, and anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitisAnn Allergy Asthma Immunol91160712952110
   PubMed Web of Science ®Google Scholar
• CorrenJCasaleTDenizY2003Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthmaJ Allergy Clin Immunol111879012532101
   PubMed Web of Science ®Google Scholar
• CruzAALimaFSarinhoE2007Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infectionClin Exp Allergy3719720717250692
   PubMed Web of Science ®Google Scholar
• DenizYMGuptaN2005Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibodyClin Rev Allergy Immunol29314816222082
   PubMed Web of Science ®Google Scholar
• DjukanovicRWilsonSJKraftM2004Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthmaAm J Respir Crit Care Med1705839315172898
   PubMed Web of Science ®Google Scholar
• DreyfusDHRandolphCC2006Characterization of an anaphylactoid reaction to omalizumabAnn Allergy Asthma Immunol96624716680936
   PubMed Web of Science ®Google Scholar
• FahyJVFlemingHeWongHH1997The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjectsAm J Respir Crit Care Med1551828349196082
   PubMed Web of Science ®Google Scholar
• FinnAGrossGvan BavelJ2003Omalizumab improves asthma-related quality of life in patients with severe allergic asthmaJ Allergy Clin Immunol1112788412589345
   PubMed Web of Science ®Google Scholar
• FoxJAHotalingTEStrubleC1996Tissue distribution and complex formation with IgE of an anti – IgE antibody after intravenous administration in cynomolguls monkeysJ Pharmacol Exp Ther279100088930210
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA)2007Global strategy for asthma management and preventionGINA Guidelines 2007Accessed October 9, 2007 URL: www.ginasthma.org
   Google Scholar
• HamelmannERolinck-WerninghausCWahnU2002From IgE to anti-IgE: where do we stand?Allergy579839412358994
   PubMed Web of Science ®Google Scholar
• HolgateSTDjukanovicRCasaleT2005Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacyClin Exp Allergy354081615836747
   PubMed Web of Science ®Google Scholar
• HumbertMBeasleyRAyresJ2005Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy603091615679715
   PubMed Web of Science ®Google Scholar
• IshizakaKIshizakaTHornbrookMM1966Physico-chemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activityJ Immunol9775854162440
   PubMed Web of Science ®Google Scholar
• JardieuPMFickRBJ1999IgE inhibition as a therapy for allergic diseaseInt Arch Allergy Immunol118112510224354
   PubMed Web of Science ®Google Scholar
• JohanssonSGOBennichH1967Immunological studies of an atypical (myeloma) immunoglobulinImmunology13381944168094
   PubMed Web of Science ®Google Scholar
• KannyGMoneret-VautrinDAFlabbeeJ2001Population study of food allergy in FranceJ Allergy Clin Immunol1081334011447395
   PubMed Web of Science ®Google Scholar
• KingCXiangliJMalhotraI1997Mice with targeted deletion of the IgE gene have increased worm burdens and reduced granulomatous inflammation following primary infection with Schistosoma mansoniJ Immunol1582943008977202
   PubMed Web of Science ®Google Scholar
• KohlerGMilsteinC1975Continuous cultures of fused cells secreting antibody of predefined specificityNature25649571172191
   PubMed Web of Science ®Google Scholar
• KrathenRAHsuS2006Failure of omalizumab for treatment of severe adult atopic dermatitisJ Am Acad Dermatol533384016021135
   PubMed Web of Science ®Google Scholar
• KuehrJBrauburgerJSchauerU2002Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitisJ Allergy Clin Immunol1092748011842297
   PubMed Web of Science ®Google Scholar
• LaneJECheyneyJMLaneTN2006Treatment of recalcitrant atopic dermatitis with omalizumabJ Am Acad Dermatol54687216384758
   PubMed Web of Science ®Google Scholar
• LeungDYBieberT2003Atopic dermatitisLancet3611516012531593
   PubMed Web of Science ®Google Scholar
• LeungDYSampsonHAYungingerJW2003Effects of anti-IgE therapy in patients with peanut allergyN Engl J Med348975612637606
   PubMed Web of Science ®Google Scholar
• LinHBoeselKMGriffithDT2004Omalizumab rapidly decreases nasal allergic response and FCɛRI on basophilsJ Allergy Clin Immunol11329730214767445
   PubMed Web of Science ®Google Scholar
• MellerupMTHahnGWPoulsenLKMallingH2000Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatmentClin Exp Allergy301423910998019
   PubMed Web of Science ®Google Scholar
• MilgromHFickRBSuJQ1999Treatment of allergic asthma with monoclonal anti-IgE antibodyN Engl J Med34119667310607813
   PubMed Web of Science ®Google Scholar
• MüllerURHelblingABerchtoldE1992Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safetyJ Allergy Clin Immunol89529341740583
   PubMed Web of Science ®Google Scholar
• NogaOHanfGKunkelG2003Immunological changes in allergic asthmatics following treatment with omalizumabInt Arch Allergy Immunol131465212759489
   PubMed Web of Science ®Google Scholar
• PastorelloEAIncorvaiaCOrtolaniC1995Studies on the relationship between the level of specific IgE antibodies and the clinical expression of allergy: I. Definition of levels distinguishing patients with symptomatic from patients with asymptomatic allergy to common aeroallergensJ Allergy Clin Immunol9658077499673
   PubMed Web of Science ®Google Scholar
• PrausnitzCKüstnerH1921Studien über UeberempfindlichkeitZentral-blatt für Bakteriol. Parasitenolog. u. Infection85 Teil 11609
   Google Scholar
• PrestaLGLahrSJShieldsRL1993Humanization of an antibody directed against IgEJ Immunol1512623328360482
   PubMed Web of Science ®Google Scholar
• Rolinck-WerninghausCHamelmannEKeilT2004The co-seasonal application of anti-IgE after preaseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic childrenAllergy59973915291906
   PubMed Web of Science ®Google Scholar
• SchulmanES2001Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disordersAm J Respir Crit Care Med164S61111704611
   PubMed Web of Science ®Google Scholar
• SiraganianRPMiddletonEReedCEEllisEFAdkinsonNFYungingerJWBusseWW1993Mechanisms of IgE-mediated hypersensitivityAllergy. Principles and practiceSt. LouisMosby10534
   Google Scholar
• SolèrMMatzJTownleyR2001The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmaticsEur Respir J182546111529281
   PubMed Web of Science ®Google Scholar
• StokesJRCasaleTB2006Allergy immunotherapy for primary care physiciansAm J Med119820317000208
   PubMed Web of Science ®Google Scholar
• UguzALackwGPumphreysR2005Allergic reactions in the community: a questionnaire survey of members of the anaphylaxis campaignClin Exp Allergy357465015969665
   PubMed Web of Science ®Google Scholar
• VignolaAMHumbertMBousquetJ2004Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLARAllergy597091715180757
   PubMed Web of Science ®Google Scholar
• VigoPGirgisKRPfuetzeBL2006Efficacy of anti-IgE therapy in patients with atopic dermatitisJ Am Acad Dermatol541687016781320
   PubMed Web of Science ®Google Scholar
• WalkerSMonteilMPhelanK2006Anti-IgE for chronic asthma in adults and childrenCochrane Database Syst Rev Apr192CD003559
   Google Scholar
• WandererAA2007A potential new therapy for cold urticaria and chronic idiopathic urticariaJ Allergy Clin Immunol11951717291869
   PubMed Web of Science ®Google Scholar
• WilsonDRTorres-LimaMDurhamS2005Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysisAllergy6041215575924
   PubMed Web of Science ®Google Scholar